Podcasts

September 2023

Prof. Paolo Ghia discusses the results of a matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia

Prof. Paolo Ghia (Università Vita Salute San Raffaele, Italy)

This HematoTalk is brought to you by the publisher of the Belgian Journal of Hematology (BJH) in partnership with AstraZeneca. NS ID XL-3698-Revision date 09/2023-LB Local code 1417

All podcasts

April 2023

BCMA targeted therapy in multiple myeloma – Dr. Julien Depaus presents a second patient case

Dr. Julien Depaus

March 2023

BCMA TARGETED THERAPY IN MULTIPLE MYELOMA – Hear the experts’ experience on the manageable adverse events

Dr. Ann Van De Velde and Prof. Michel Delforge

February 2023

BCMA targeted therapy in multiple myeloma – Listen to a first patient case from Dr. Julien Depaus

Dr. Julien Depaus

February 2023

Dr. Isabelle Vande Broek discusses the results of two recent subgroup analyses of the IKEMA trial

Dr. Isabelle Vande Broek, VITAZ hospital, Sint-Niklaas

February 2023

BCMA targeted therapy in multiple myeloma – Meet the expert’s real-life experience on efficacy and QoL

Dr. Natalie Put and Prof. Michel Delforge

January 2022

ASH 2021

Time-limited venetoclax and ibrutinib for patients with R/R CLL and undetectable MRD

Prof. Carsten Niemann, Department of Clinical Medicine, University of Copenhagen, Denmark

January 2022

ASH 2021

Talha Munir about ibrutinib plus venetoclax vs chlorambucil plus obinutuzumab for CLL patients

Dr. Talha Munir, Leeds Teaching Hospital NHS Trust, Leeds, United Kingdom

September 2021

Clinical trials

Prof. Susan O’Brien about the value of acalabrutinib in CLL

Prof. Susan O’Brien, University of California Irvine, United States

August 2021

UPDATE CLL

Dr. Davide Rossi: “How to optimize the first-line treatment for patients with CLL?”

Dr. Davide Rossi, Deputy Head of the Division of Hematology of the Oncology Institute of Southern Switzerland IOSI and Head of the Laboratory of Experimental Hematology at the Institute of Oncology Research IOR in Bellinzona, Switzerland

1 2 Next

Category

Disorder

Year

Podcasts

Prof. Paolo Ghia discusses the results of a matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia

Prof. Paolo Ghia (Università Vita Salute San Raffaele, Italy)

All podcasts

BCMA targeted therapy in multiple myeloma – Dr. Julien Depaus presents a second patient case

Dr. Julien Depaus

BCMA TARGETED THERAPY IN MULTIPLE MYELOMA – Hear the experts’ experience on the manageable adverse events

Dr. Ann Van De Velde and Prof. Michel Delforge

BCMA targeted therapy in multiple myeloma – Listen to a first patient case from Dr. Julien Depaus

Dr. Julien Depaus

Dr. Isabelle Vande Broek discusses the results of two recent subgroup analyses of the IKEMA trial

Dr. Isabelle Vande Broek, VITAZ hospital, Sint-Niklaas

BCMA targeted therapy in multiple myeloma – Meet the expert’s real-life experience on efficacy and QoL

Dr. Natalie Put and Prof. Michel Delforge

Time-limited venetoclax and ibrutinib for patients with R/R CLL and undetectable MRD

Prof. Carsten Niemann, Department of Clinical Medicine, University of Copenhagen, Denmark

Talha Munir about ibrutinib plus venetoclax vs chlorambucil plus obinutuzumab for CLL patients

Dr. Talha Munir, Leeds Teaching Hospital NHS Trust, Leeds, United Kingdom

Prof. Susan O’Brien about the value of acalabrutinib in CLL

Prof. Susan O’Brien, University of California Irvine, United States

Dr. Davide Rossi: “How to optimize the first-line treatment for patients with CLL?”

Dr. Davide Rossi, Deputy Head of the Division of Hematology of the Oncology Institute of Southern Switzerland IOSI and Head of the Laboratory of Experimental Hematology at the Institute of Oncology Research IOR in Bellinzona, Switzerland